Abstract Library

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,

#4324 The diagnostic and prognostic value of 68Ga-DOTANOC and 18F-FDG PET/CT for thymic carcinoids

Introduction: Thymic carcinoid (ThC) is an extremely rare type of neuroendocrine tumour. There is insufficient evidence to evaluate ThC using 68Ga-DOTANOC and 18F-FDG PET/CT.

Conference:

Presenting Author: Xu J

Authors: Xu J, Liang Y, Chen J, Song S,

Keywords: SSTR, FDG, PET/CT, thymic carcinoid,

#3511 Predictive factors of adverse events onset in GEP-NET patients treated with LRT

Introduction: Since metastatic GEP-NET are low-growing neoplasms, characterised by stability followed by progression, multiple lines of treatment have to be adopted to control distant localisations and symptoms. In this scenario, there are no precise models to assess the occurrence of adverse events during LRT (Ligand Radiotherapy).

Conference:

Presenting Author: Scalorbi F

Authors: Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V,

Keywords: lrt, toxicity, logistic regression, predictive model, gep-net,

#3443 Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy

Introduction: Non-invasive tools to improve prognostication are warranted in patients with neuroendocrine neoplasms (NEN). Expression of urokinase plasminogen activator receptor (uPAR) is present in many cancer types and associated with a poor outcome, but largely unknown in NEN. uPAR-targeted radionuclide therapy has proven effective in preclinical models and uPAR may be a potential target in NEN patients.

Conference:

Presenting Author: Carlsen E

Authors: Carlsen E, Loft M, Loft A, Berthelsen A, Langer S,

Keywords: urokinase plasminogen activator receptor (upar), neuroendocrine neoplasm, pet, prognosis, molecular imaging,

#3107 Predicting response after [166Ho]-radioembolization in patients with neuroendocrine tumor liver metastases using neutrophil-to-lymphocyte and thrombocyte-to-lymphocyte ratios

Introduction: Response after treatment with [166Ho]-radioembolization is difficult to predict in patients with NET. Neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR) have been described as prognosticators for response.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, objective response, NLR, TLR,